Cardiotoxicity induced by anthracyclines
Conditions
Interventions
Test group:Anthracycline-containing chemotherapy + SWXLH Granules
Control Group:Anthracycline-containing chemotherapy + placebo
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed B-cell lymphoma. 2. No gender restrictions; aged =18 years, with an expected survival time of =6 months. 3. Eligible for chemotherapy and scheduled to receive =4 cycles of anthracycline-containing regimen. 4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1. 5. Adequate organ function and clinically assessed as able to tolerate chemotherapy. 6. Voluntary participation in the study with informed consent and good compliance.
Exclusion criteria
Exclusion criteria: 1. Having received >2 cycles of anthracycline-containing chemotherapy prior to enrollment 2. Use of HER-2 targeted therapy or PD-1/PD-L1 inhibitors within the past 1 year, or receipt of thoracic radiotherapy within the past 3 years. 3. Malignant arrhythmia or New York Heart Association (NYHA) Class III/IV heart failure. 4. Individuals with alcohol abuse, psychoactive substance misuse, drug abuse, or dependence. 5. Pregnant or lactating women, individuals allergic to the study drug or its components, or patients with psychiatric disorders. 6. Currently participating in or having participated in another clinical trial within the past 3 months. 7. Other individuals deemed unsuitable for enrollment by physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of cardiac injury caused by anthracyclines; | — |
Secondary
| Measure | Time frame |
|---|---|
| echocardiographic;Seattle Angina Scale;Progression free survival (PFS);ECG examination; | — |
Countries
China
Contacts
Public ContactHuiming Yu
Beijing Cancer Hospital
Outcome results
None listed